This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
A growing body of research has cited high Deep TMS therapy success rates, finding that BrainsWay’s Deep Transcranial Magnetic Stimulation (dTMS) can alleviate symptoms of a number of mental health conditions. Such studies rely on meticulous, evidence-based analysis whose results have been published in prestigious medical journals.
Studies on Deep TMS leverage gold-standard benchmarks, such as double-blind, randomized control trials (RCT) and multicenter patient arms to maximize their objectivity. One such study from 2015, published in World Psychiatry, received data from 20 different academic mental health centers to examine dTMS’s effect on treatment-resistant participants battling Major Depressive Disorder (MDD).
The multicenter pivotal RCT, which was the foundation for BrainsWay receiving FDA-clearance for MDD treatment, found that roughly one out of three participants achieved remission after four weeks of dTMS treatment included in the acute phase. This was true even among patients who had previously failed to sufficiently improve from three or more antidepressant medications.
Additionally, over 80% experienced a response (or improvement) during the following continuation phase.
Deep TMS was found to have an even greater efficacy within real-life clinical settings, i.e. among patients receiving treatment in the field. Of recorded data for over 1000 participants undergoing a course of dTMS treatment for MDD, some 75% of participants achieved a clinical response, with one out of two achieving remission.
BrainsWay dTMS technology has also been clinically validated to treat OCD. A study published in 2019 in the American Journal of Psychiatry found that a six-week course of BrainsWay’s Deep TMS treatment offers significant clinical improvement of OCD symptoms, with results similar to those of a 12-week pharmacotherapy treatment course. Greater than one in three patients achieved a significant reduction in OCD symptoms, including those who had previously been unresponsive to medication and/or psychotherapy. As such, dTMS was found to be a well-tolerated treatment that can offer about the same level of relief as medication, only in half the time.
It is safe to combine dTMS therapy with antidepressant medication or psychotherapy, with dTMS also found to offer relief when part of a combined treatment course. That said, a great deal of the research performed on Deep TMS treatment underscores its effectiveness in cases where people were found to be unresponsive to psychotherapy or SSRI medication.
In a recent study from 2019, published by the Journal of Psychiatric Research, dTMS therapy combined with standard medication for MDD was found to be significantly more effective than standard pharmacotherapy alone, reducing the symptoms of close to two-thirds of participants battling MDD. These results highlight dTMS’s ability to enhance existing treatments when administered under professional medical supervision.
Finally, a growing body of research suggests that TMS conducted during or in proximity to psychotherapy can increase the efficacy of both treatments’ combined effect.
With more and more research carried out, Deep TMS therapy’s high success rate is becoming more solidified, as the positive effects this innovative technology can have on people’s lives are becoming clearer and broader.
Read more about Deep TMS studies.